Promoter holding
64.27%
ML
Morpheus Life Sciences Private Limited - Due diligence report
A 360° intelligence report on Morpheus Ivf: trust score, financial health, credit view, compliance, directors, growth and distress signals -…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Morpheus Ivf — 360° Intelligence Report
Generated from MCA filings & public records58/100
Trust Score
Moderate
Morpheus Ivf is assessed as Moderate with a Trust Score of 58/100. Morpheus Ivf is an active private limited indian non-government company incorporated in 2009, operating in the Healthcare sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.
Report generated on 31 Jul 2026 from the latest processed filings. Morpheus Life Sciences Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
58/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
70/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
5/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
40/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Negative operating earnings - debt service depends on external support.
Charges position: 6 open (3.41 cr) · 1 satisfied (11.75 Lakh).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 6 | 48.0 cr |
| Kotak Mahindra Prime Limited | 1 | 48.0 cr |
Compliance Score: 70/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- 2 auditor resignation(s) filed - latest: N. A. Shah Associates LLP on 2023-07-24.
- Delayed payments to MSME suppliers disclosed (86 disclosure(s)).
- 1 active GST registration(s).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| FRANK HERMANN RIEMER | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MILIND MAKARAND VAIDYA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MICHAEL KARL HEINZ MARIA DUMSCHAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJ NAUTAM PAREKH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARVIND LAVKAMD CHANDRA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 5 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Ivf International Der Deutschen Klink Fur Fortpflanzungsmedizin Gmbh
Subsidiaries
-
Group entities
-
Capital events
33 allotment(s) · 4 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Morpheus Chaitanya Fertility Center Llp | Subsidiary Company | 74.00% |
| Ivf International Der Deutschen Klink Fur Fortpflanzungsmedizin Gmbh | Holding Company | 74.00% |
| Morpheus Aakriti International Ivf Center | Subsidiary Company | 74.00% |
| Morpheus Abirami International Ivf Center Llp | Subsidiary Company | 74.00% |
| Morpheus Anandlok International Ivf Center Llp | Subsidiary Company | 74.00% |
| Morpheus Bliss Fertility Center Llp | Subsidiary Company | 74.00% |
| Morpheus Gayatri International Ivf Center Llp | Subsidiary Company | 74.00% |
| Morpheus Ivf Medihope International Ivf Center Llp | Subsidiary Company | 74.00% |
| Morpheus Kasturi International Ivf Center Llp | Subsidiary Company | 74.00% |
| Morpheus Kolkata International Ivf Center Llp | Subsidiary Company | 74.00% |
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 40 · Distress 40
Growth signals & trust indicators
Operating for 17+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Negative net worth.
6 open charge(s) registered - assets are encumbered.
2 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 10.76 Lakh.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence57/100
Review suggested
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 3 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment37/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 6 open charge(s) of 3.41 cr already registered.
- Compliance record supports lending.
Investor view32/100
Limited indicators at present
Growth quality and scalability through an investor lens.
- No clear growth signals in the filed years.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
04 Jan 2023
Securities allotted
863209 Equity Shares - 1.29 cr raised
25 Nov 2022
Director ceased
UDIT SURESH MITTAL
12 Aug 2022
Securities allotted
76686 Equity Shares - 7.67 Lakh raised
15 Jun 2022
Securities allotted
163431 Equity Shares - 26.15 Lakh raised
11 May 2022
Director ceased
ASHISH CHANDRAKANT MODI
28 Apr 2022
Securities allotted
317259 Equity Shares - 50.76 Lakh raised
31 Mar 2022
Share transfer (FY 2022)
574691.00000000 shares to Siddharth Bharat Daftary
Share transfer (FY 2022)
574586.00000000 shares to Aarti Gautam Daftary
26 Oct 2020
Securities allotted
284900 Debentures - 85.47 Lakh raised
07 Aug 2020
Charge created
Hdfc Bank Limited - 50.00 Lakh
14 Jul 2020
Charge created
Hdfc Bank Limited - 25.60 Lakh
31 Mar 2020
Share transfer (FY 2020)
574586.00000000 shares to Gautam Vinod Daftary
Share transfer (FY 2020)
574691.00000000 shares to Bharat Vinod Daftary
10
Key Observations
Auto-generated from the data aboveRevenue declined 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
5 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 33 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Ratkal Speciality Hospitals Private Limited | U85100KA2011PTC057981 | Bangalore, Karnataka, India |
| Eroth Technologies Private Limited | U74999DL2020PTC360583 | Newdelhi, Delhi, India |
| Vasco Teleradiology Private Limited | U85200RJ2021PTC075446 | Jaipur, Rajasthan, India |
| Top-Notch Health Care Products Pvt Ltd | U85199KL1991PTC006266 | Ernakulam, Kerala, India |
| Aakriti Labs Private Limited | U85195RJ2004PTC019563 | Jaipur, Rajasthan, India |
| Asian Institute Of Nephrology And Urology (Chennai) Private Limited | U85100MH2017PTC466706 | Hyderabad, Telangana, India |
| Meesha Health-Care & Research Private Limited | U74999MH2013PTC249185 | Mumbai, Maharashtra, India |
| Nutrihealthsystems | U85190DL2009PTC188895 | New Delhi, Delhi, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Morpheus Ivf before audits and certifications: compliance score 70/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Morpheus Ivf: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Enhanced diligence advised. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Morpheus Ivf - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 58/100, distress signals and MSME payment-delay disclosures - know whether Morpheus Ivf pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Morpheus Ivf - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Morpheus Ivf an active company?
Morpheus Ivf has MCA status “Active” with a compliance score of 70/100 (Moderate).
Is Morpheus Ivf financially healthy?
Morpheus Ivf has a Financial Health Score of 5/100 (Caution Indicated) based on its filed financial statements.
Should I do business with Morpheus Ivf?
Its overall Trust Score is 58/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Morpheus Ivf?
The ultimate holding entity is Ivf International Der Deutschen Klink Fur Fortpflanzungsmedizin Gmbh. 5 active director(s) are on record.
Does Morpheus Ivf have loans or charges against its assets?
6 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Morpheus Ivf up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 70/100 (Moderate).
Is it risky to lend to Morpheus Ivf?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
